MultiplexDX has signed a contract with the leading Central European healthcare group AGEL on supplies of its qPCR tests for SARS-CoV2. The AGEL group will use the tests in commercial testing for COVID-19 within its network of eight hospitals in Slovakia - AGEL SK.
MultiplexDX will supply two types of tests from its portfolio to the AGEL SK hospital network as part of the contract. In addition to the rTEST Covid-19 qPCR Multiplex, which was also validated by the Dutch National Institute for Public Health and Ecology. The second type of tests under contract is rTEST Covid-19 / Flu qPCR, which can detect and distinguish both COVID-19 and influenza strains: Influenza A and Influenza B.
You can find out more about our test portfolio in the Products section.
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.